Investing Profile

Florian Müllershausen

InvestorVC
Managing Director at Novartis Venture Fund
nvfund.comBasel, Switzerland
Photo of Florian Müllershausen, Managing Director at Novartis Venture Fund

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
Novartis Venture Fund Managing Director
$5.0M - $10.0M
$7.5M
13
$750M
CompanyStageDateRound SizeTotal Raised
Artios Pharma
Series DNov 2025$120M
Series CJul 2021$150M
Series BAug 2018$83M
$380M
Co-investors: René Kuijten (EQT Life Sciences), Raphael Wisniewski (Andera Partners), Barbara Dalton (Pfizer Venture Investments), Hakan Goker (M Ventures (Merck)), Nikola Trbovic (Pfizer Venture Investments), Jake Simson (RA Capital)
NRG Therapeutics
Series BSep 2025$68M
$86M
Co-investors: Laurence Barker (SV Health Investors), Jonathan Tobin (Brandon Capital Partners)
FoRx Therapeutics
Series AJun 2025$49M
SeedApr 2020$11M
$110M
Co-investors: Therese Liechtenstein (MDC Ventures (formerly KBS Ventures)), Vincent Ossipow (Omega Funds), Denis Patrick (Pfizer Venture Investments), Vincent Brichard
Rhygaze
Series AJan 2025$86M
SeedJul 2024$11M
$97M
Co-investors: David Schenkein (GV (Google Ventures)), Daniela Couto (BGV (BioGeneration Ventures))
Citryll
Series BDec 2024$90M
$110M
Co-investors: Edward Van Wezel (BGV (BioGeneration Ventures)), Isabelle de Cremoux (Seventure Partners), Geert-Jan Mulder (Forbion)
LOQUS23 THERAPEUTICS
Series AOct 2024$46M
SeedNov 2021$9M
$55M
Co-investors: Rogier Rooswinkel (Forbion)
Amphista Therapeutics
Series BMar 2021$53M
$61M
Co-investors: Satish Jindal (Advent Life Sciences), Raj Parekh (Advent Life Sciences), Rogier Rooswinkel (Forbion)
Anaveon
Series AFeb 2019$35M
$160M
Co-investors: Jasper Bos (Forbion), Ohad Hammer (Pontifax Venture Capital), Denis Patrick (Pfizer Venture Investments)
Ruhr University Bochum Dr. rer. nat. (PhD)
Freie Universität Berlin Diploma (eq. to MSc